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Abstract
A specific and sensitive serodiagnostic test for Mycobacterium ulcerans infection would greatly assist the diagnosis of Buruli
ulcer and would also facilitate seroepidemiological surveys. By comparative genomics, we identified 45 potential M. ulcerans
specific proteins, of which we were able to express and purify 33 in E. coli. Sera from 30 confirmed Buruli ulcer patients, 24
healthy controls from the same endemic region and 30 healthy controls from a non-endemic region in Benin were screened
for antibody responses to these specific proteins by ELISA. Serum IgG responses of Buruli ulcer patients were highly variable,
however, seven proteins (MUP045, MUP057, MUL_0513, Hsp65, and the polyketide synthase domains ER, AT propionate,
and KR A) showed a significant difference between patient and non-endemic control antibody responses. However, when
sera from the healthy control subjects living in the same Buruli ulcer endemic area as the patients were examined, none of
the proteins were able to discriminate between these two groups. Nevertheless, six of the seven proteins showed an ability
to distinguish people living in an endemic area from those in a non-endemic area with an average sensitivity of 69% and
specificity of 88%, suggesting exposure to M. ulcerans. Further validation of these six proteins is now underway to assess
their suitability for use in Buruli ulcer seroepidemiological studies. Such studies are urgently needed to assist efforts to
uncover environmental reservoirs and understand transmission pathways of the M. ulcerans.
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Introduction
Mycobacterium ulcerans is the causative agent of the severe
necrotizing skin disease known as Buruli ulcer (BU). The clinical
presentation of the disease begins with the appearance of a small,
painless, nodule or papule. As the infection progresses, necrosis of
subcutaneous fat and eventual breakdown of skin occurs leading to
the appearance of a characteristic ulcer with an undermined edge
[1,2]. BU has been reported in more than 30 countries world-
wide, although the primary burden of disease is carried by those in
western and sub-Saharan Africa [3]. Since the 1980s there has
been a rapid re-emergence of the disease, where in some endemic
regions it is now more common than the two other major
mycobacterial diseases, tuberculosis and leprosy [4]. The victims
of this disease are most commonly children, although any
individual may be affected [5,6]. Whilst control efforts are
underway in many affected countries, a major shortcoming is
the lack of a simple, rapid method to confirm infection with M.
ulcerans.
The necrosis of subcutaneous fat seen in BU is due to the actions
of a family of polyketide toxins known as mycolactones. These toxins
possess cytotoxic and immunosuppressive activities and injection of
purified mycolactone into animal models replicates the pathology
seen in human BUs [7,8]. Mycolactones are produced by large
polyketide synthases encoded on the pMUM series of megaplasmids
in members of theM. ulcerans/Mycobacterium marinum complex known
as mycolactone producing mycobacteria (MPM) [9,10]. Three
polyketide synthase genes (mlsA1, mlsA2 and mlsB) encode the
mycolactone synthesis machinery, whilst a number of accessory
genes that appear essential for mycolactone production are also
present on the pMUM plasmids [9]. Furthermore, these plasmids
contain a number of predicted protein-coding DNA sequences
(CDS), with products of unknown function, the majority of which
are conserved amongst different strains of MPM [11]. Several studies
indicate that all the MPM (including M. ulcerans) diverged from a
common M. marinum progenitor, through acquisition of the pMUM
plasmid [10,12,13].M. marinum strains share greater than 98%DNA
identity with M. ulcerans [10,12,13] but they do not contain pMUM
and do not make mycolactone, although someMPM that were given
species names prior to the discovery of pMUM plasmids are
confusingly referred to as M. marinum, M. ‘‘liflandii’’ and M.
pseudoshottsii [14,15,16]. For simplicity, here all mycolactone
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producing mycobacteria are referred to asM. ulcerans and the closely
related, non-mycolactone producing strains are referred to as M.
marinum, in accordance with recent recommendations [17].
There are several laboratory-based methods for the diagnosis of
BU in humans. These strategies currently include the direct
examination of Ziehl-Neelsen stained smears, culture of M. ulcerans
and PCR from swabs or tissue samples. Microscopy based on the
Ziehl-Neelsen stain from BU swabs or biopsies is quick, however,
several studies have shown that the sensitivity of this method is
highly variable (40 – 80%, depending on the laboratory) [18,19].
Culture of M. ulcerans from a suspect lesion remains the gold
standard for diagnosis, however, due to the long incubation times
required (up to 12 weeks) and low sensitivity it is not appropriate
for pre-treatment diagnosis [20]. PCR for the M. ulcerans specific
insertion sequence IS2404 was first validated as a diagnostic test in
1997 [21] and several studies have shown it to be the most
sensitive of the currently employed diagnostic techniques
[20,22,23]. However, high reagent costs and the need for
specialized equipment and trained staff to perform and interpret
PCR restricts its use to larger, central laboratories. Thus none of
these approaches are suited for use in rural African regions where
BU is endemic and the World Health Organization has designated
the development of new approaches to the diagnosis of M. ulcerans
infection a research priority.
Early attempts to develop diagnostics for BU relied upon
injection of Burulin (a crude M. ulcerans whole cell lysate) into
individuals and waiting for the development of a delayed-type
hypersensitivity response, akin to the Mantoux test [24]. Whilst
those in the active stage of disease had strong reactions to Burulin,
the majority also reacted to PPD, suggesting that there was
significant cross-reactivity amongst mycobacterial antigens. Sub-
sequently it was shown that BU patients develop serum antibodies
to whole cell lysate of M. ulcerans [25], as well as culture filtrate
proteins [26,27]. However, these studies also found that up to 37%
of control subjects had positive antibody responses to M. ulcerans
proteins, again indicating that a significant degree of cross
reactivity with other mycobacteria exists [25,26,27].
We reasoned that the identification of specific M. ulcerans
antigens may help to overcome some of the difficulties associated
with cross-reactivity to conserved mycobacterial antigens and
accelerate efforts to develop a rapid diagnostic test. A recent
increase in the number of mycobacterial genome sequences
available has provided an opportunity to comprehensively identify
proteins that are unique to M. ulcerans. We identified 45 M. ulcerans
candidate antigens and then used PCR to assess their distribution
in 26 M. ulcerans and 30 M. marinum strains. We then determined
the reactivity of these proteins to sera from BU patients by ELISA.
Here we show that a subset of these proteins is conserved amongst
all M. ulcerans strains and that some of these proteins may be useful
in seroepidemiological studies of Buruli ulcer.
Methods
Ethics statement
Ethics approval for serum collection was obtained from the
National Ethics Committee of the Ministry of Health in Benin and
the Human Ethics Committee of the Faculte´ des Sciences de la Sante´,
University of Abomey-Calavi, Benin. Informed consent was obtained
for every participant. For children involved in this study, written,
informed consent was obtained from their parents or legal guardians.
Bacterial strains
Cloning of M. ulcerans unique sequences was performed in E. coli
TOP10 cells (Invitrogen). The mycobacterial strains used in this
study and their characteristics are listed in Table S1.
Identification of M. ulcerans unique genes
Sequences unique to M. ulcerans were identified first by
bioinformatic comparisons between the M. ulcerans genome and
other recently completed mycobacterial genomes, using BLAS-
TCLUST as described [28]. The completed and unfinished
genomes utilized in this study were (Name, Genbank accession
number): M. abcessus CIP104536 (NC_010397), M. avium subsp.
paratuberculosis K10 (NC_002944), M. bovis BCG str. Pasteur
1173P2 (NC_008769), M. gilvum PYR-GCK (NC_009338),
M. intracellulare ATCC 13950 (NZ_ABIN00000000), M. kansasii
ATCC 12748 (NC_ACBV00000000), M. leprae TN (NC_002677),
M. marinum M (NC_010612), M. smegmatis mc2 155 (NC_008596),
Mycobacterium sp. KMS (NC_008705), Mycobacterium sp. JLS
(NC_009077), Mycobacterium sp. MCS (NC_008146), M. tuberculosis
C (NZ_AAKR00000000), M. tuberculosis CDC 1551 (NC_002755),
M. tuberculosis F11 (NC_009565), M. tuberculosis H37Rv
(NC_000962), M. tuberculosis H37Ra (NC_009525), M. tuberculosis
Haarlem (NZ_AASN00000000), M. avium 104 (GenBank acces-
sion NC_008595), M. ulcerans Agy99 (NC_008611), and M.
vanbaalenii PYR-1 (NC_008726). Forty-seven chromosomally
encoded sequences and 54 plasmid-encoded sequences were
initially selected as being M. ulcerans specific with no ortholog
present in any other mycobacterial genome. Orthologues were
defined as predicted amino acid sequences with greater than 85%
amino acid identity to M. ulcerans proteins. Further criteria were
applied to restrict the number of coding sequences (CDS) to
investigate (see results section). Due to the high level of genetic
relatedness between M. ulcerans and M. marinum strains, M. marinum
and M. ulcerans strains spanning the known genetic diversity were
then tested for these CDS by PCR using standard conditions and
the addition of 5% dimethyl sulfoxide.
DNA cloning and sequencing
Primers were designed to selected CDS to include a 59 CACC
sequence for cloning into the Gateway entry vector pENTR/SD/
Author Summary
Buruli ulcer is a slowly progressive but potentially
devastating disease of skin and subcutaneous tissue
caused by the bacterium Mycobacterium ulcerans. The
disease is widespread throughout West and Central Africa,
and some countries in the region have established Buruli
ulcer control programs. Buruli ulcer is difficult to distin-
guish from other chronic skin conditions that require
different treatments, and there is an urgent need for an
accurate point-of-care diagnostic test. In this study, we
have used genomic techniques to identify 45 potential M.
ulcerans–specific antigens, 33 of which we have been able
to produce and purify. We tested these proteins against
sera from patients, healthy people living in the same
region as the patients and from individuals living in a
region with no cases of Buruli ulcer. We found that seven
proteins were able to elicit antibody responses that were
significantly different between patients and the control
subjects from the non-endemic region but not from the
healthy individuals in the same Buruli ulcer endemic
region. Further analysis showed that six of these M.
ulcerans proteins might be useful as markers of exposure
to M. ulcerans and could be developed into tools to
uncover environmental reservoirs and understand trans-
mission pathways of the bacterium.
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D-TOPO (Invitrogen) (see Table S2 for a list of oligonucleotides
used in this study). CDS were PCR amplified using either Pfu
Turbo (Stratagene) or KOD (Novagen) DNA polymerases under
standard reaction conditions. Gateway cloning reactions were
performed according to the manufacturer’s instructions into the
entry vector pENTR/SD/D-TOPO and positive clones were
confirmed to be in-frame by DNA sequencing. Subcloning of the
sequences of interest into one of three different E. coli expression
vectors, pDEST17, pET-DEST42 or pBAD-DEST49 (Invitro-
gen), was accomplished using LR clonase enzyme (Invitrogen)
according to manufacturer’s instructions.
Protein expression
For pDEST17 or pET-DEST42 constructs, overnight cultures
of E. coli Rosetta 2 (Novagen), Rosetta-gami (Novagen), or C43
[29] containing the cloned expression constructs were grown and
used to inoculate 200 ml volumes of Luria-Bertani broth
containing 100 mg/ml ampicillin and 30 mg/ml chloramphenicol.
Cells were grown at 37uC with shaking until they reached an
optical density at 600 nm of approximately 0.8, at which point
they were induced with IPTG (Isopropyl b-D-1-thiogalactopyr-
anoside) at a final concentration of 1 mM. Cultures were
incubated for a further 4 hrs at 37uC with shaking. Cells were
then harvested by centrifugation.
For expression of proteins from pBAD-DEST49, E. coli DH10B
cultures containing the appropriate constructs were grown as
described above (without the addition of chloramphenicol) and
were induced with a final concentration of 0.2% L-arabinose.
Polyhistidine-tagged protein purification
Recombinant M. ulcerans fusion proteins that displayed high
levels of expression from either of the three expression vectors
were purified under denaturing conditions using Talon metal
affinity resin (Clontech). Briefly, cell pellets from 200 ml cultures
post-induction were resuspended in 10 ml wash buffer (300 mM
NaCl, 50 mM NaH2PO4, 8M urea, pH 7.0). Samples were
sonicated on ice for 3630s and the sonicate was then pelleted for
20 min at 12,5006 g. The clarified lysate was added to 1 ml
prepared resin and incubated at room temperature for 30 min.
The solution was drained from the column and the column was
washed with 5 ml of wash buffer for 10 min at room temperature
with gentle agitation. This was repeated twice, after which the
protein was eluted from the column in wash buffer containing
150 mM imidazole, followed by a final elution using wash buffer
containing 200 mM imidazole. Eluates were analyzed by SDS-
PAGE and dialyzed against wash buffer to remove imidazole.
Sera collection
Serum samples were collected from 93 individuals, comprising
three groups. Group 1 (Patient group) consisted of 30 BU patients
living in villages near the Oue´me´ river in the Oue´me´ province of
Benin, where Buruli ulcer is highly prevalent (8–20 cases per 1000
individuals [30]). The patients (11 female and 19 male, aged 3–74
years) were recruited from the Centre de Diagnostic et de
Traitement de l’Ulce`re de Buruli in Pobe`, Benin. Diagnosis of
Buruli ulcer was made by Ziehl-Neelsen staining of material taken
from swabs of the lesions or directly from biopsy material and
subsequently confirmed by IS2404 PCR. Group 2 (Endemic
Controls) consisted 24 participants (14 female and 10 male aged 5–
72 years) with no history of BU but from the same villages in the
Oue´me´ province as the patients. Group 3 (Non-endemic Controls)
consisted of 30 participants (15 female and 15 male), living in
villages around Ouidah (Atlantic province), a non-endemic coastal
area for BU in Benin, approximately 150 km southwest of Pobe`
[30]. BCG vaccination exposure (based on the presence of a scar)
for all three groups was approximately 60%. Serum was prepared
from 8 ml of blood for each participant and aliquots of each
sample were stored at 280uC.
SDS-PAGE and Western blotting
For analysis of purified protein reactivity by western blotting,
purified proteins were separated by SDS-polyacrylamide gel
electrophoresis (PAGE) on 12% polyacrylamide gels under
reducing conditions, as described previously [31]. The gel was
then transferred to nitrocellulose membranes in Tris-glycine buffer
containing 20% methanol. Membranes were blocked in 5% skim
milk, PBS with 0.1% Tween-20. Membranes were then incubated
with human sera at 1/500 dilution. Prior to incubation with anti-
human IgG horseradish-peroxidase (HRP) conjugated secondary
antibody, the membranes were washed repeatedly in PBS-0.1%
Tween-20. Bands were detected by chemiluminescence using the
Western lightning kit (Perkin Elmer).
Detection of human antibodies against potential M.
ulcerans antigens by ELISA
Purified recombinant M. ulcerans proteins were adsorbed to
polystyrene 96-well plates (Costar, Corning) at 0.5 mg per well in
carbonate coating buffer (pH 9.6) and incubated at 4uC overnight.
Plates were washed five times with PBS (pH 7.2) containing 0.05%
Tween 20 (Sigma-Aldrich) (PBS-T) and then five times with PBS
before being blocked with 100 ml 5% fetal bovine serum in PBS.
Plates were washed as described above and 50 ml human sera
(diluted 1/100 in PBS with 0.5% BSA) was added to each well.
Plates were incubated for 2 hrs at room temperature before being
washed as described above. 50 ml of goat anti-human IgG-HRP
(Millipore) diluted at 1/2500 in PBS with 0.5% BSA was added to
each well and incubated at room temperature for 1 hr, followed by
washing as described above. Plates were developed by the addition
of 50ul of ABTS solution (Invitrogen) to each well, incubated for 5
minutes and the reaction was stopped by the addition of 50 ml of
0.01% sodium azide, 0.1M citric acid. The colour change reaction
was measured at 405 nm in Multiskan Ascent microplate reader
(Thermo Fisher Scientific). Positive control wells were incubated
with anti-6xHis-HRP antibody (Roche Applied Science).
Data analysis
ELISA test results were analysed using GraphPad Prism version
5.0c (GraphPad Software, San Diego California USA). One-way
ANOVA with Bonnferroni’s post-test was used to compare OD
values for patient, endemic controls and non-endemic control
groups whose distributions approximated normality. ELISA data
with non-gaussian distributions were analysed by the Kruskal-
Wallis test with Dunn’s post test. Cut-off scores for determination
of inclusion of proteins for analysis were determined as the mean
OD of the control population. Receiver-operator characteristic
(ROC) analysis was used to determine the best cut-off value and
associated sensitivity and specificity that discriminated individuals
living in BU endemic areas from those living in non-endemic
areas.
Results
Identification of potential M. ulcerans antigens
Forty-seven chromosomally-encoded CDS, potentially unique
to M. ulcerans were identified by bioinformatic comparison of the
M. ulcerans genome to 21 other mycobacterial genomes (see
Materials and Methods for genomes used). We then excluded
CDS ,50 codons in length and the insertion sequence elements
Identification of Novel M. ulcerans Antigens
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IS2404 and IS2606 and also applied the following criteria to
include only those CDS likely to generate an immune response: i)
predicted membrane association; ii) predicted secretion signal; or
iii) previously confirmed as expressed in a proteomic study [32],
resulting in 34 chromosomal CDS of interest. We also identified
33 unique CDS on the pMUM001 plasmid and in addition we
included in our analysis the sequences encoding the 12 unique
functional domains of the mycolactone polyketide synthases
(MlsA1, MlsA2 & MlsB) as representative of the entire genetic
variability present in this locus [9].
Due to the close genetic relationship between M. ulcerans and M.
marnium and the knowledge that M. marinum M, does not reflect the
genetic diversity in the M. marinum complex [10], 30 genetically
diverse M. marinum isolates were tested for the presence of the
selected chromosomal CDS by PCR. The M. marinum strains do
not contain pMUM plasmids, so these isolates were not tested for
the presence of any of the plasmid CDS. Eleven of the CDS
identified as M. ulcerans specific by bioinformatic comparisons were
found to be present in at least one of the other M. marinum strains
tested and were thus excluded from further analyses (Table 1).
The pMUM plasmids are known to vary in both size and gene
content between M. ulcerans strains [11,33], and so we tested a
selection of 26 geographically distinct M. ulcerans isolates, by PCR,
for the presence of each of the plasmid sequences (Table 1).
Additionally, we examined these strains for the presence of each of
the selected chromosomal sequences by PCR, and found that six
of the plasmid CDS and four of the chromosomally encoded CDS
were present in all of the M. ulcerans strains tested (Table 1).
Because the focus of our study is to develop diagnostic reagents for
use in African patients where the need for BU control is most
urgent, we particularly focused on the distribution of sequences of
interest in African isolates of M. ulcerans. The 23 M. ulcerans specific
chromosomal CDS were found in all 10 of the African M. ulcerans
strains tested. As expected, the plasmid-borne mycolactone
polyketide synthase (mls) sequences were found in all M. ulcerans
strains tested, and also 32 of 33 non-mls plasmid sequences were
present in all African strains. MUP038 was absent by PCR from a
single African strain (M. ulcerans strain Kob), which confirms
previous findings for this strain showing it has a plasmid DNA
deletion [33] (Table 1).
The completed list of M. ulcerans unique CDS selected for
further study included 13 chromosomal and 30 plasmid CDS (12
mls and 18 non-mls) and is shown in Table S3. In addition we
included as positive controls two CDS encoding proteins Hsp65
and Hsp18 (MUL_2232) which have been reported to be antigenic
but which are present in other mycobacteria species [34,35]. This
resulted in a total of 45 proteins under investigation.
Cloning, expression and purification of M. ulcerans
sequences in E. coli
All 45 of these selected M. ulcerans sequences were amplified
from strain Agy99 genomic DNA and 44 were cloned using the
Gateway system into at least one of three different expression
vectors, pDEST17 (N-terminal 6xHis tag), pET-DEST42 (C-
terminal 6xHis tag) or pBAD-DEST49 (N-terminal thioredoxin
tag, C-terminal 6xHis tag). We then successfully expressed 37 of 44
(84.1%) of the target sequences in E. coli as either N-terminal or C-
terminal 6xHis tagged proteins or both at or near their predicted
molecular weight (Table S3). Whilst 37 proteins could be
expressed in quantities sufficient for western blotting, only 33 of
these 37 were able to be produced in quantities sufficient for
ELISA analysis.
Seven proteins were unable to be expressed in E. coli as either N-
or C-terminal 6xHis tagged fusions. Expression of two of these
proteins (MUP016 and MUP017) from either pDEST17 or pET-
DEST42 proved to be toxic to E. coli. Sequencing of the remaining
five constructs showed in-frame fusions had been made and
western blots on WCLs of E. coli bearing these constructs showed
an absence of recombinant protein expression after induction (data
not shown). Further attempts were made to salvage these seven
proteins by cloning into pBAD-DEST49, a vector with arabinose
inducible expression, an N-terminal thioredoxin tag and a C-
terminal 6xHis tag, designed to improve protein expression and
solubility, and by using E. coli strain C43, which has been
Table 1. Percentage of M. marinum and M. ulcerans strains
containing selected M. ulcerans Agy99 sequences.
CDS
% MMb
strains
% MUc
strains
% MUc
African
strains CDS
% MUc
strains
% MUc
African
strains
MUL_0027 3.7 - - MUP002 100 100
MUL_0076 51.8 - - MUP003 100 100
MUL_0503 92.6 - - MUP004 100 100
MUL_0508 0 88.5 100 MUP006 80.8 100
MUL_0510 0 88.5 100 MUP007 92.3 100
MUL_0511 0 92.3 100 MUP013 92.3 100
MUL_0512 0 84.6 100 MUP014 88.5 100
MUL_0513 0 84.6 100 MUP015 96.2 100
MUL_0515 0 76.9 100 MUP016 80.8 100
MUL_0516 0 88.5 100 MUP017 61.5 100
MUL_0517 0 96.2 100 MUP018 80.8 100
MUL_0526 29.6 - - MUP019 73.1 100
MUL_0527 48.1 - - MUP020 80.8 100
MUL_0551 0 73.1 100 MUP021 88.5 100
MUL_0552 0 88.5 100 MUP023 100 100
MUL_0998 0 92.3 100 MUP024 100 100
MUL_0999 0 92.3 100 MUP038 92.3 90
MUL_1001 0 92.3 100 MUP045 100 100
MUL_1135 7.5 - - MUP046 96.2 100
MUL_2590 44.4 - - MUP057 46.2 100
MUL_2831 0 100 100 MUP064 46.2 100
MUL_2832 0 96.2 100 MUP065 53.8 100
MUL_3210 74.1 - - MUP066 88.5 100
MUL_3212 0 100 100 MUP067 73.1 100
MUL_3214 0 96.2 100 MUP068 65.4 100
MUL_3215 0 92.3 100 MUP070 65.4 100
MUL_3216 0 96.2 100 MUP071 88.5 100
MUL_3217 0 100 100 MUP074 88.5 100
MUL_3218 0 69.2 100 MUP075 88.5 100
MUL_3230 0 100 100 MUP076 84.6 100
MUL_3440 66.6 - - MUP078 92.3 100
MUL_3828 0 69.2 100 MUP079 92.3 100
MUL_4213 44.4 - - MUP080 96.2 100
MUL_4217 44.4 - - PKS
domainsa
100 100
a = All sequences encoding the 12 PKS domains are found in 100% of
mycolactone producing mycobacteria.
b =M. marinum;
c =M. ulcerans.
doi:10.1371/journal.pntd.0000872.t001
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optimized for the expression of toxic or membrane proteins
[29,36]. However, these efforts were also unsuccessful and so these
proteins were unable to be produced to levels sufficient for
purification.
Diagnostic potential of M. ulcerans specific antigens
To evaluate the potential for these proteins to be used to
diagnose M. ulcerans infection or assess exposure to the bacterium,
sera was collected from 39 IS2404 PCR confirmed BU patients
(designated: patient) and 24 controls with no past or current
diagnosis of BU (designated: endemic control). Both these groups
came from the high BU prevalence Oue´me´ region in Benin. Sera
were also obtained from 30 additional control subjects who lived in
the BU non-endemic Ouidah region of Benin (designated:
control). A pre-study decision was taken to analyze in these three
groups rather than only patients versus non-endemic controls as
previous studies had indicated the possibility of asymptomatic
exposure to M. ulcerans in BU endemic areas [34].
Screening of 33 proteins by ELISA uncovered significantly
higher IgG antibody responses in patients compared to non-
endemic controls for the following seven proteins; MUP045,
MUP057, MUL_0513, Hsp65, and the mycolactone Mls domains
(AT-propionate, ER, and KR-A domains) (p,0.05, Figure 1).
However, IgG responses of the endemic controls were not
significantly different to those of patients for any of the seven
proteins (Figure 1). Endemic controls had IgG responses that were
significantly higher than those of non-endemic controls for the six
of these seven proteins, suggesting that residents of endemic
regions with no history of BU might have been exposed to M.
ulcerans. The remaining 26 proteins, including the positive control
antigen MUL_2232 (Hsp18), had no ability to elicit discriminatory
antibody responses between any groups (Figure S1).
When serum antibody responses for the proteins shown in
Figure 1 were analysed according to disease state (i.e, plaque,
plaque and oedema, ulcer, or plaque and ulcer), there was no
significant difference in reactivity between disease state and
endemic controls for each protein except for ER (Figure 2). Mean
ELISA absorbance values for sera from patients with ulcers were
significantly higher in their reactivity to the ER domain of the
mycolactone PKS than endemic controls and other lesion types
(p,0.05, Figure 2).
Seroepidemiological potential of M. ulcerans specific
antigens
We examined six of the seven proteins shown in Figure 1 to test
if they could effectively distinguish subjects from BU endemic and
BU non-endemic regions of Benin. We performed receiver-
operator curve (ROC) analyses for each of these six antigens by
combining the ELISA absorbance values for patient and endemic
control groups (collectively referred to as BU-endemic) (Table 2) to
calculate sensitivity and the non-endemic control group for
specificity. ROC curves for each of the six proteins are shown in
Figure 3. The ELISA OD cutoffs that maximized the accuracy of
each of the six antigens are shown in Table 2 and the results
indicated that a number of these proteins might be useful in
determining new M. ulcerans endemic areas. In particular
MUL_0513 and two of the Mls domains (AT-propionate, KR-B)
all produced high area under curve (AUC, .0.8), and good
sensitivity (.70%) and specificity (.80%). However the best
antigen was Hsp65, with AUC of 0.932, 84.1% sensitivity and
93.3% specificity at an OD cut-off of 0.693. Hsp65 also had the
highest likelihood ratio (12.6), indicating that an individual living
in a BU endemic area is 12.6 times more likely to have a positive
Hsp65 test than an individual residing in a non-endemic area.
Discussion
The current diagnostic delay experienced by Buruli ulcer
patients contributes to morbidity and increased economic hardship
[37]. A diagnostic test that is rapid, inexpensive, sensitive, specific
and suitable for in-field use would facilitate the timely diagnosis of
BU and is a World Health Organization (WHO) research priority.
Current laboratory diagnostics including culture, PCR, AFB
microscopy and histopathology all have various limitations. We
have used comparative genomics to identify M. ulcerans specific
sequences to explore the usefulness of the encoded proteins for use
in the serodiagnosis of Buruli Ulcer in endemic areas of West
Africa.
Whilst bioinformatic methods were initially used to identify M.
ulcerans specific CDS, eleven of these ‘‘M. ulcerans specific’’ CDS
were found in at least one of theM. marinum strains tested (Table 1).
These CDS are distributed across the M. ulcerans genome, and
were all situated within regions of DNA that are not present in the
M. marinum M genome. It is interesting to note that some of these
sequences appear restricted to certain M. marinum sequence types
that are genetically closer to M. ulcerans than the sequenced M.
marinum M strain. For example MUL_4213 was restricted to the
ST3 and ST5 strains tested and MUL_0027 was restricted to the
ST3 strains tested. Some of these sequences may be useful as
genotyping tools to more clearly delineate the relationships
between M. ulcerans and M. marinum strains. These findings are
consistent with the known high genetic relatedness of M. ulcerans
and M. marinum [10,13], and underlies the need for experimental
validation of bioinformatic results.
Only nine M. ulcerans specific sequences were conserved
amongst all mycolactone producing mycobacterial strains tested.
However, in agreement with previous findings that African M.
ulcerans strains form a close genetic complex with relatively little
variation at the whole genome level [38,39,40], all selected
chromosomal genes were present in all African M. ulcerans isolates
that were examined. As pMUM plasmids are known to vary in size
and gene content between M. ulcerans strains [11,33], it is not
surprising that only six of 33 non-PKS CDS were completely
conserved. However, plasmid CDS may be the most specific to M.
ulcerans as they appear to be restricted to mycolactone producing
mycobacteria.
During the course of this work the sequences of two other
pMUM plasmids from MPM became available [11] and revealed
a number of differences between these plasmids with regards to the
potential antigens chosen for this study. These differences can
explain the inability to detect some of the selected CDS in MPM
strains. For example, MUP006 orthologs in pMUM002 and
pMUM003 contain a different 59 nucleotide sequence, explaining
the absence of a PCR product in some MPM strains. Conversely,
MUP068 and MUP070 orthologs in pMUM001 and pMUM002
contain different 39 nucleotide sequences. Furthermore, MUP065
appears to be a pseudogene in pMUM001, as its ortholog in
pMUM002 and pMUM003 are significantly longer, and MUP067
is deleted from pMUM002 and pMUM003. All of these examples
serve to highlight the genetic variability in the non-PKS
component of these pMUM plasmids.
In this study 44 M. ulcerans specific sequences were cloned with
37 (84%) of these successfully expressed in E. coli. Seven proteins
were unable to be expressed in multiple E. coli strains, and the lack
of overexpressed protein was confirmed by western blotting (data
not shown). Similar studies that have attempted to identify novel
CDS in M. avium subsp. paratuberculosis have also shown variable
rates of production of 6 x His tagged proteins (between 25 – 69%
of cloned CDS able to be expressed) [41,42], indicating that this
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tag may reduce expression of certain proteins. Furthermore, all
proteins in this study were found to be insoluble under the
expression conditions used, and six of the seven proteins that were
unable to be expressed were predicted to be integral membrane
proteins, with overexpression of these proteins possibly leading to
toxicity. Both of these problems have been previously described in
other mycobacterial protein expression studies [43,44,45]. Clearly,
further optimization of the expression of these proteins, including
Figure 1. ELISA results for seven M. ulcerans proteins capable of discriminating between patients and controls. Comparison of patient,
endemic control (EC) and non-endemic control sera reactivity to seven M. ulcerans antigens that showed an ability to discriminate between patient
and control sera. Mean OD405nm readings for each group and standard error of the mean are shown. The horizontal dotted line in each figure
represents the mean OD405nm reading of the control group. * = p,0.05.
doi:10.1371/journal.pntd.0000872.g001
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the use of alternate proteins tags or different host-based expression
systems (including mycobacteria) may be necessary to obtain
useable amounts of protein for future testing. Recently, a
Gateway-based vector has been developed for the overexpression
of proteins in M. smegmatis and has shown that proteins which were
previously insoluble in E. coli could be expressed in soluble form in
M. smegmatis [46]. Furthermore, M. tuberculosis proteins have been
successfully produced in the methylotrophic yeast Pichia pastoris
with enhanced patient serum reactivity compared with those
produced in E. coli [47,48]. The future use of either of these
systems for the proteins that proved difficult to produce in this
study may be warranted to investigate their antigenicity.
We were able to confirm that patients with BU had significantly
greater IgG antibody responses to seven of 33 purified M. ulcerans
proteins as determined by ELISA compared with a control group
(Figure 1). The inability of the remaining 26 proteins to
discriminate between patients and controls is likely due to either
the inability of a particular protein to elicit an antibody response
or through shared epitopes with proteins from other sources
leading to cross-reactive antibody responses. However, none of the
proteins were able to discriminate between patients and control
subjects from the same BU-endemic area and are therefore
unlikely to be useful as a diagnostic test for M. ulcerans infection. By
combining measurements of antibody responses to six antigens
from people living in a BU endemic area, we were able to
discriminate between subjects resident in endemic areas of Benin
and controls living in a non-endemic area. Although it remains a
possibility that these data reflect cross-reactive antibody responses
to other mycobacteria, we suggest that the most likely interpre-
tation of these findings is that many residents of BU-endemic areas
have been exposed to M. ulcerans.
Somewhat surprisingly, the most discriminatory antigen was
Hsp65, which has 94% homology to the same protein from M.
tuberculosis, whilst antigens with no orthologues in other mycobac-
teria had lower sensitivity and specificity. Hsp65 is known to be an
immunodominant antigen in the antibody response to mycobac-
teria [35] and we anticipated that all groups would have had
significant levels of exposure to other mycobacteria from either
BCG vaccination, tuberculosis infection, and from exposure to
other environmental mycobacteria. We therefore anticipated that
Hsp65 would be a sensitive but non-specific antigen. There may
be several explanations for our findings. Firstly, patients and
endemic controls were both from a region of high BU prevalence
and therefore may have been recently and/or frequently exposed
to M. ulcerans, leading to continual boosting of antibody responses
that does not occur in the non-endemic control group. The fact
that M. ulcerans elicits responses dominated by antibodies to Hsp65
at all stages of the infection in mice supports this hypothesis (35).
Alternatively, it is possible that our patient and control groups
differed in their exposure to mycobacteria other than M. ulcerans,
and therefore the results do not reflect M. ulcerans specific antibody
responses.
The small heat shock protein, Hsp18, had previously been
identified as an immunodominant antigen that may be useful for
predicting exposure to M. ulcerans [34]. Results from the current
study, however, showed that Hsp18 was not able to discriminate
between individuals living in an endemic area and those who
reside in a non-endemic area. The reasons for these differences are
unclear, however, a possible explanation may be that here,
antibody responses were quantified by ELISA, as opposed to
qualitative western blot analysis in the study by Diaz et al [34].
Although the other antigens we identified as M. ulcerans specific
by our comparative genomic approach did not appear to be as
sensitive or specific as Hsp65 in predicting individuals living in a
Figure 2. Analysis of BU patient serum reactivity by disease
state. Patient antibody responses were analysed by disease state for
the mycolactone polyketide synthase ER domain. Means and SEM of
each group are shown. * = p,0.05.
doi:10.1371/journal.pntd.0000872.g002
Table 2. Receiver-operator characteristics for proteins with predictive value for living in a BU endemic area.
Antigen AUCa 95% CI Cut-off Sensitivity (%) Specificity (%) Likelihood ratiob NPVc
MUP045 0.810 0.720–0.901 0.824 57.1 90.0 5.7 0.61
MUP057 0.753 0.652–0.854 0.893 39.7 93.5 6.2 0.57
MUL_0513 0.873 0.799–0.946 0.622 74.6 86.7 5.6 0.70
Hsp65 0.932 0.873–0.991 0.693 84.1 93.3 12.6 0.77
AT propionate 0.897 0.832–0.962 0.896 79.4 86.7 6.0 0.70
KR A 0.856 0.777–0.934 0.850 69.8 83.3 4.2 0.68
aAUC, area under curve;
bLikelihood ratio represents the likelihood that someone with a positive test will live in a BU endemic area, i.e. a likelihood ratio of 5.0 means someone with a positive
test is 5 times more likely live in BU endemic area than an individual with a negative test;
cNPV, negative predictive value.
doi:10.1371/journal.pntd.0000872.t002
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Buruli endemic area, they nevertheless did show that significant
antibody responses were detectable, and three antigens
(MUL_0513, AT-propionate, KR-B) showed significant ability to
discriminate individuals living in a BU endemic versus non-
endemic area. Their use in combination may show additive effects
and, in conjunction with case-control studies, may permit the
development of an assay for detecting individuals exposed to M.
ulcerans. More research in this direction would greatly assist efforts
to uncover environmental reservoirs and understand transmission
pathways of the bacterium.
Although a number of M. ulcerans specific sequences were
investigated in this study, there were still a large number that were
initially ruled out based on predictions of their cellular location or
function. It is possible that some of these potential antigens may be
good candidates for further analysis. Based on our findings of high
response rates among patient and endemic control groups it
appears unlikely that serological approaches will be useful for
diagnosing Buruli ulcer. Indeed, the development of serodiagnos-
tics for other mycobacterial diseases, such as tuberculosis, has
proved difficult and many of the currently available serodiagnos-
tics for mycobacteria have limited usefulness in the clinic [49,50].
An alternative to BU serodiagnosis may be possible via direct
antigen detection approaches. The extent and distribution of
antigens within M. ulcerans lesions or within a patients circulation
has not been defined, however, there is the possibility that some of
the unique proteins described in this present study may be able to
be developed as the basis for antigen capture assays. A diagnostic
test based on this methodology would overcome the problems of
cross-reactivity seen with tests based upon antibody responses, and
would be more appropriate for resource limited areas than tests
based on T-cell responses. This project has helped define the
antigenic repertoire of M. ulcerans and research is continuing in this
vein to investigate the feasibility of other diagnostic modalities.
Supporting Information
Figure S1 ELISA results for 26 M. ulcerans proteins that showed
no significant difference in reactivity between patients, endemic
controls or non-endemic controls. Reactivity of individual patient
and endemic control (EC) samples are shown. Mean reactivity of
non-endemic control sera group is represented by a dotted
horizontal line across each graph. Mean OD405 nm readings for
each group and standard error of the mean are also shown.
Found at: doi:10.1371/journal.pntd.0000872.s001 (0.15 MB PDF)
Table S1 List of bacterial strains used in this study.
Found at: doi:10.1371/journal.pntd.0000872.s002 (0.12 MB
DOC)
Table S2 Oligonucleotides used in this study.
Found at: doi:10.1371/journal.pntd.0000872.s003 (0.08 MB
DOC)
Table S3 M. ulcerans genes tested in this study.
Found at: doi:10.1371/journal.pntd.0000872.s004 (0.06 MB
DOC)
Figure 3. Receiver operator characteristic (ROC) analysis of six M. ulcerans specific proteins. ROC curves are shown for the six M. ulcerans
specific proteins detailed in Figure 1 (MUP045, MUP057, MUL_0513, Hsp65, AT propionate and KR A).
doi:10.1371/journal.pntd.0000872.g003
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